Insilico Medicine

About Insilico Medicine

Insilico Medicine is a biotechnology company focused on transforming drug discovery and development using generative artificial intelligence to significantly reduce the time and cost of bringing life-saving medications to patients. Their mission is to extend healthy productive longevity for everyone.

Products & Services

PandaOmics:An AI-driven platform for therapeutic target and biomarker discovery.

PandaOmics Box:A specialized version of PandaOmics for target discovery.

Chemistry42:A generative AI software for drug discovery, focusing on chemistry and molecule design.

Generative Biologics:A platform for designing biologics using generative AI.

Science42:DORA:An AI tool for scientific research and drug discovery automation.

inClinico:A platform for predicting clinical trial outcomes using multi-modal AI.

Nach01:A foundation model for generative chemistry innovation.

PreciousGPT:A multimodal transformer-based model for aging research and target discovery.

Specialties

Generative Artificial Intelligence Drug Discovery Target Identification Biomarker Discovery Aging Research Therapeutic Pipeline Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series E T: - FT: Series E	A: 110000000 MR: - FA: $110 million FAN: 110000000	D: 2025-03-13 FD: 2025-03-13	1 investors

Series E Latest

2025-03-13

$110.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alex Zhavoronkov

Chairman of the Board, Executive Director and CEO

F

Feng Ren

Chief Scientific Officer, Executive Director & Co-CEO

A

Alex Aliper

President

M

Michelle Chen

Chief Business Officer

S

Sujata Rao

Chief Medical Officer

L

Leo Shi

Non-executive Director

View 12 more team members with Pro

Unlock Full Team Directory

Recent News